The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown
Sahar Ashrafzadeh,1 Bradley S Gundlach,1 Irena Tsui2– 4 1David Geffen School of Medicine, University of California, Los Angeles, CA, USA; 2Ophthalmology Department, West Los Angeles Veterans Health Administration, Los Angeles, CA, USA; 3Retina Division, Stein Eye Institute, University of California,...
Guardado en:
Autores principales: | Ashrafzadeh S, Gundlach BS, Tsui I |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b143e38fc14c489ab861b6a11b174196 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
por: Andrea Montesel, et al.
Publicado: (2021) -
Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021) -
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016) -
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
por: Yannuzzi NA, et al.
Publicado: (2019) -
Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
por: Almeida DRP, et al.
Publicado: (2021)